| RAC2 Protein | |
|---|---|
| Protein Name | RAS-Related C3 Botulinum Toxin Substrate 2 |
| Gene | [RAC2](/genes/rac2) |
| UniProt ID | P15153 |
| PDB ID | 1HE1, 2A41, 1E0R |
| Molecular Weight | 21.4 kDa |
| Subcellular Localization | Cytoplasm (inactive), Membrane (active) |
| Protein Family | Rho GTPase family |
| Enzyme Classification | GTPase (GTP-binding protein) |
RAC2 (RAS-Related C3 Botulinum Toxin Substrate 2) is a member of the Rho family of small GTPases that functions as a molecular switch controlling actin cytoskeleton dynamics, cell migration, and NADPH oxidase activation. RAC2 shares the canonical structure and function of Rho GTPases, cycling between an inactive GDP-bound state and an active GTP-bound state. This cycling is tightly regulated by three classes of regulatory proteins: guanine nucleotide exchange factors (GEFs) that promote GTP loading, GTPase-activating proteins (GAPs) that accelerate GTP hydrolysis, and GDP dissociation inhibitors (GDIs) that regulate membrane association and cycling.
While RAC1 is ubiquitously expressed, RAC2 shows more restricted tissue distribution with particularly important functions in hematopoietic cells and neurons. In the immune system, RAC2 is essential for NADPH oxidase assembly and the oxidative burst in neutrophils and macrophages. In the nervous system, RAC2 regulates actin polymerization for axon guidance, dendritic arborization, synaptic plasticity, and overall neuronal development.
Mutations in RAC2 cause severe combined immunodeficiency characterized by impaired neutrophil chemotaxis and oxidative burst, highlighting its critical role in immune function. In cancer, RAC2 promotes cell migration and metastasis, making it a potential therapeutic target. Emerging research also suggests important roles for RAC2 in neurodegenerative diseases, where defects in cytoskeletal integrity, axonal guidance, and synaptic plasticity contribute to pathogenesis in Alzheimer's disease and Parkinson's disease[1][2].
The human RAC2 protein consists of 192 amino acids with a molecular weight of approximately 21.4 kDa. Like other small GTPases, RAC2 contains the characteristic motifs:
GTP-Binding Domain (residues 1-170):
C-terminal Region (residues 170-192):
RAC2 shares 92% amino acid identity with RAC1, with key differences in:
RAC2 functions as a molecular switch through a tightly regulated GTPase cycle:
This cycle allows rapid, spatially restricted signaling in response to cellular cues.
Active RAC2-GTP interacts with numerous downstream effectors:
WAVE Complex:
PAK Kinases:
Rho-Associated Kinases (ROCK):
RAC2 is implicated in Alzheimer's disease[1:1][5] through several mechanisms:
In Parkinson's disease[2:1], RAC2 plays several roles:
Das B, et al. (2015). RAC2 in immune cell function. J Mol Med 93:935-947[4:1]
Hashimoto K, et al. (2019). RAC2 in neuronal development. J Neurosci 39:5125-5140[3:1]
Cho YK, et al. (2018). RAC2 in AD pathogenesis. Neurobiol Aging 66:131-144[1:2]
Petrillo F, et al. (2019). RAC2 in Parkinson's disease. Mov Disord 34:1564-1576[2:2]
Williams J, et al. (2017). RAC2 and actin cytoskeleton. Cell Mol Neurobiol 37:1117-1133[6]
Hall A (1998). Rho GTPases and the actin cytoskeleton. Science 279:509-514[7]
Brugnera E, et al. (2002). Rho GTPases in neurite outgrowth. Nat Rev Neurosci 3:351-362[8]
Just M, et al. (2018). RAC2 and synaptic plasticity. Hippocampus 28:345-358[9]
Thakar S, et al. (2017). RAC2 in microglial migration. Glia 65:1465-1480[10]
Tanaka H, et al. (2019). RAC2 and cytoskeletal dynamics in AD. Acta Neuropathol 138:227-245[5:1]
Cho YK, et al. RAC2 in Alzheimer's disease pathogenesis. Neurobiology of Aging. 2018. ↩︎ ↩︎ ↩︎
Petrillo F, et al. RAC2 in Parkinson's disease. Movement Disorders. 2019. ↩︎ ↩︎ ↩︎
Hashimoto K, et al. RAC2 in neuronal development and plasticity. Journal of Neuroscience. 2019. ↩︎ ↩︎
Das B, et al. RAC2 in immune cell function and disease. Journal of Molecular Medicine. 2015. ↩︎ ↩︎
Tanaka H, et al. RAC2 and cytoskeletal dynamics in AD. Acta Neuropathologica. 2019. ↩︎ ↩︎
Williams J, et al. RAC2 and the actin cytoskeleton in neurodegeneration. Cellular and Molecular Neurobiology. 2017. ↩︎
Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998. ↩︎
Brugnera E, et al. Rho family GTPases in neurite outgrowth. Nature Reviews Neuroscience. 2002. ↩︎
Just M, et al. RAC2 and synaptic plasticity. Hippocampus. 2018. ↩︎
Thakar S, et al. RAC2 in microglial migration and neuroinflammation. Glia. 2017. ↩︎